FEMASYS INC Files 8-K Report
Ticker: FEMY · Form: 8-K · Filed: Mar 6, 2024 · CIK: 1339005
| Field | Detail |
|---|---|
| Company | Femasys Inc (FEMY) |
| Form Type | 8-K |
| Filed Date | Mar 6, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
Femasys filed an 8-K. Check for updates.
AI Summary
On March 6, 2024, FEMASYS INC filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific financial figures or material events beyond the filing itself were detailed in the provided text.
Why It Matters
This filing indicates that FEMASYS INC is providing updates or disclosures to the SEC, which could contain important information for investors regarding the company's operations or financial status.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification and does not contain information about specific risks or material events.
Key Players & Entities
- FEMASYS INC (company) — Registrant
- 0001140361-24-011613 (filing_id) — Accession Number
- March 6, 2024 (date) — Date of Report
- 3950 Johns Creek Court, Suite 100, Suwanee, Georgia 30024 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for FEMASYS INC?
The filing is a Current Report (8-K) pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting "Other Events" and "Financial Statements and Exhibits" as of March 6, 2024.
What is the exact name of the registrant?
The exact name of the registrant is FEMASYS INC.
In which state was FEMASYS INC incorporated?
FEMASYS INC was incorporated in Delaware.
What is the business address of FEMASYS INC?
The business address is 3950 Johns Creek Court, Suite 100, Suwanee, Georgia 30024.
What is the telephone number for FEMASYS INC?
The telephone number is (770) 500-3910.
Filing Stats: 433 words · 2 min read · ~1 pages · Grade level 10.6 · Accepted 2024-03-06 09:09:27
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share FEMY The Nasdaq Stock Mar
Filing Documents
- ef20023361_8k.htm (8-K) — 30KB
- ef20023361_ex99-1.htm (EX-99.1) — 14KB
- 0001140361-24-011613.txt ( ) — 185KB
- femy-20240306.xsd (EX-101.SCH) — 4KB
- femy-20240306_lab.xml (EX-101.LAB) — 22KB
- femy-20240306_pre.xml (EX-101.PRE) — 16KB
- ef20023361_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events On March 6, 2024, Femasys Inc. (the "Company") issued a press release announcing completion of first in-office commercial procedure with the FDA-cleared FemaSeed infertility solution . A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of Femasys Inc. dated Mach 6, 2024
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Femasys Inc. By: /s/ Kathy Lee-Sepsick Names: Kathy Lee-Sepsick Title: Chief Executive Officer Date: March 6, 2024